查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1211054

全球 T 細胞淋巴瘤市場規模調查和預測：按淋巴瘤類型、治療類型和地區分析，2022-2029 年

Global T-Cell Lymphoma Market Size study & Forecast, by Lymphoma Type, Therapy Type and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

2021 年全球 T 細胞淋巴瘤市場價值約為 15.8889 億美元，預計在 2022-2029 年預測期內將以超過 8.25% 的健康增長率增長。

T 細胞淋巴瘤是一種在稱為 T 細胞的免疫系統中發展的血癌。 由於淋巴癌發病率上升、T 細胞淋巴瘤特異性療法的進步以及自身免疫性疾病導致的淋巴瘤風險等因素，T 細胞淋巴瘤市場正在擴大。 該市場由強生公司（Janssen Pharmaceuticals, Inc.）、諾華公司、百時美施貴寶公司、默克公司和 F. Hoffman Brothers, Inc. 主導。 Inc. 和 F. Hoffmann-La Roche Ltd.

由於血癌的增加，T 細胞淋巴瘤的患病率也在增加。 根據白血病和淋巴瘤協會 (R) (LLS) 的數據，美國大約三分之一的人被診斷出患有白血病、淋巴瘤或骨髓瘤。 預計到 2021 年，美國將有 186,400 人被診斷出患有白血病、淋巴瘤和骨髓瘤。 在美國 2021 年新診斷的 1,898,160 例癌症中，預計將有 9.8% 的白血病、淋巴瘤和骨髓瘤新病例。 此外，高價產品和免疫檢查點抑製劑的採用，以及多種新型治療劑的推出以及商業產品的擴展標籤，預計將在未來幾年增加這一市場機會。 然而，高昂的治療成本和治療藥物的不良副作用阻礙了整個 2022-2029 年預測期內的市場增長。

全球 T 細胞淋巴瘤市場研究中考慮的主要區域是亞太地區、北美、歐洲、拉丁美洲和世界其他地區。 由於品牌產品的主導地位和該地區疾病流行率的增加，北美在收入方面佔據了市場主導地位。 根據Globocan 2020報告，2020年加拿大發生非霍奇金淋巴瘤8506例，死亡313例。 預計這將增加該國 T 細胞淋巴瘤的發病率。 由於疾病增多、免疫系統薄弱、網民健康意識增強以及政府和非營利組織積極參與市場空間等因素，預計亞太地區在預測期內將以最高複合年增長率增長。

這項研究的目的是定義近年來各個細分市場和國家的市場規模，並預測它們在未來幾年的價值。 該報告旨在捕捉被調查國家工業的定性和定量方面的情況。

它還提供了關鍵方面的詳細信息，例如決定市場未來增長的驅動因素和挑戰。 此外，它還包含供利益相關者投資的微觀市場潛在機會，以及對主要參與者的競爭格局和產品供應的深入分析。

內容

第 1 章執行摘要

  • 市場概況
  • 2019-2029 年各細分市場的全球市場估計和預測
    • T 細胞淋巴瘤市場：按地區劃分，2019-2029 年
    • T 細胞淋巴瘤市場（按淋巴瘤類型）：2019-2029
    • 按治療類型劃分的 T 細胞淋巴瘤市場：2019 年至 2029 年
  • 主要趨勢
  • 調查方法
  • 調查先決條件

第 2 章 T 細胞淋巴瘤的全球市場定義和範圍

  • 調查的目的
  • 市場定義和範圍
    • 調查範圍
    • 工業發展
  • 調查年份
  • 貨幣兌換率

第 3 章全球 T 細胞淋巴瘤市場動態

  • T 細胞淋巴瘤的市場影響分析 (2019-2029)
    • 市場驅動力
      • 淋巴癌發病率上升
      • T 細胞淋巴瘤特異性治療的進展
      • 自身免疫性疾病導致的淋巴瘤風險
    • 市場挑戰
      • 高昂的治療費用
      • 治療劑的有害副作用
    • 市場機會
      • 採用高端產品和免疫檢查點抑製劑
      • 推出幾種新的治療藥物並擴大現有產品的適應症

第 4 章全球 T 細胞淋巴瘤市場行業分析

  • 波特 5 力模型
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭公司之間的敵對關係
  • 波特 5 力模型的未來方法 (2019-2029)
  • 害蟲分析
    • 政治
    • 經濟的
    • 社交
    • 技術
  • 頂級投資機會
  • 關鍵成功策略
  • 行業專家的展望
  • 分析師的結論和建議

第 5 章風險評估：COVID-19 的影響

  • 評估 COVID-19 對行業的總體影響
  • COVID-19 之前和 COVID-19 之後的市場情景

第 6 章全球 T 細胞淋巴瘤市場，按淋巴瘤類型

  • 市場概況
  • T 細胞淋巴瘤的全球市場：按淋巴瘤類型進行性能潛力分析
  • 2019-2029 年全球 T 細胞淋巴瘤市場，按淋巴瘤類型估計和預測
  • T 細胞淋巴瘤市場，細分市場分析
    • 外周T細胞淋巴瘤
    • T 細胞淋巴母細胞淋巴瘤

第 7 章：全球 T 細胞淋巴瘤市場：按治療類型分類

  • 市場概況
  • 全球 T 細胞淋巴瘤市場：按治療類型、性能潛力分析
  • 2019-2029 年全球 T 細胞淋巴瘤市場，按治療類型估計和預測
  • T 細胞淋巴瘤市場，細分市場分析
    • 放射治療
    • 化療
    • 免疫療法
    • 幹細胞移植
    • 其他類型的治療

第 8 章全球 T 細胞淋巴瘤市場：區域分析

  • T 細胞淋巴瘤市場，按地區劃分的市場概況
  • 北美
    • 美國
      • 按淋巴瘤類型估計和預測，2019-2029
      • 2019-2029 年按治療類型估算和預測
    • 加拿大
  • 歐洲 T 細胞淋巴瘤市場概況
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲地區
  • 亞太地區 T 細胞淋巴瘤市場概況
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 拉丁美洲 T 細胞淋巴瘤市場概況
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地區
  • 世界其他地方

第 9 章衝突信息

  • 頂級市場策略
  • 公司簡介
    • Genmab AS
      • 主要信息
      • 概覽
      • 財務信息（取決於數據可用性）
      • 產品概覽
      • 近期趨勢
    • Johnson & Johnson（Janssen Pharmaceuticals Inc.）
    • Mundipharma International, Limited
    • Bristol-Myers Squibb Company
    • Autolus Therapeutics PLC
    • Acrotech Biopharma, Inc.
    • Macopharma
    • Merck & Co. Inc.
    • F. Hoffmann-La Roche Ltd
    • Novartis AG

第 10 章研究過程

  • 研究過程
    • 數據挖掘
    • 分析
    • 市場評估
    • 驗證
    • 出版
  • 調查屬性
  • 調查先決條件

Global T-Cell Lymphoma Market is valued at approximately USD 1588.89 million in 2021 and is anticipated to grow with a healthy growth rate of more than 8.25% over the forecast period 2022-2029. T-Cell Lymphoma is a type of blood cancer which arises in an immune system named as T-cell. The T-Cell Lymphoma market is expanding because of factors such as rise in lymphoma cancer incidence, advancements in T-cell lymphoma-specific therapies and the risk of lymphoma due to autoimmune disorders. This market is dominated by Johnson & Johnson (Janssen Pharmaceuticals Inc.), Novartis AG, Bristol Myers Squibb Company, Merck & Co. Inc., and F. Hoffmann-La Roche Ltd.

The rising number of blood cancer has increased the prevalence of T-cell lymphoma. As per the Leukemia & Lymphoma Society® (LLS), about one in three people in the United States is diagnosed with leukaemia, lymphoma, or myeloma. In 2021, a total of 186,400 people in the United States are expected to be diagnosed with leukaemia, lymphoma, or myeloma. New cases of leukaemia, lymphoma, and myeloma are expected to account for 9.8% of the estimated 1,898,160 new cancer cases diagnosed in the United States in 2021. Furthermore, the uptake of premium-priced products and immune checkpoint inhibitors as well as the launch of several novel therapies with label extensions of commercialized products are expected to increase the opportunity for this market in the forthcoming years. However, the high cost of Treatment and Adverse Side Effects of Therapies stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global T-Cell Lymphoma Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the region's increasing disease prevalence. According to the Globocan 2020 report, 8,506 cases of non-Hodgkin's lymphoma occurred in Canada in 2020, with 313 deaths. This is expected to increase the incidence of T-cell lymphoma in the country. Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising disease, weak immune systems, rising health awareness among the netizen and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:

Genmab AS

Johnson & Johnson (Janssen Pharmaceuticals Inc.)

Mundipharma International, Limited

Bristol-Myers Squibb Company

Autolus Therapeutics PLC

Acrotech Biopharma, Inc.

Macopharma

Merck & Co. Inc.

F. Hoffmann-La Roche Ltd

Novartis AG

Recent Developments in the Market:

  • In September 2021, Soligenix Inc. announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Drug Development granted orphan drug designation to hypericin for the treatment of T-cell lymphoma (CTCL).
  • In December 2020, the FDA approved her new drug application for LB1901. It's an investigational chimeric antigen receptor T-cell therapy for the treatment of adults with relapsed or refractory Cutaneous T-cell lymphoma.
  • In July 2020, miRagen Therapeutics Inc. announced that the Food and Drug Administration (FDA) granted orphan drug designation to cobomarsen for the treatment of her T-cell lymphoma. Cobomarsen is being developed by miRagen in two clinical programs for the treatment of different types of T-cell lymphoma, including a Phase 2 trial in cutaneous T-cell lymphoma (CTCL) and a Phase 1 trial in adult T-cell lymphoma. inhibitor (ATLL) Ultraviolet.

Global T-Cell Lymphoma Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Lymphoma Type, Therapy Type, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Lymphoma Type:

Peripheral T-cell Lymphoma

T-cell Lymphoblastic Lymphoma

By Therapy Type:

Radiotherapy

Chemotherapy

Immunotherapy

Stem Cell Transplantation

Other Types of Therapies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

RoLA

Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Million)
    • 1.2.1. T-Cell Lymphoma Market, by Region, 2019-2029 (USD Million)
    • 1.2.2. T-Cell Lymphoma Market, by Lymphoma Type, 2019-2029 (USD Million)
    • 1.2.3. T-Cell Lymphoma Market, by Therapy Type, 2019-2029 (USD Million)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global T-Cell Lymphoma Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global T-Cell Lymphoma Market Dynamics

  • 3.1. T-Cell Lymphoma Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rise in Lymphoma Cancer Incidence
      • 3.1.1.2. Advancements in T-cell Lymphoma-specific Therapies
      • 3.1.1.3. Risk of Lymphoma due to Autoimmune Disorders
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Treatment
      • 3.1.2.2. Adverse Side Effects of Therapies
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Uptake Of Premium-Priced Products and Immune Checkpoint Inhibitors
      • 3.1.3.2. Launch Of Several Novel Therapies with Label Extension of Commercialized Products

Chapter 4. Global T-Cell Lymphoma Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global T-Cell Lymphoma Market, by Lymphoma Type

  • 6.1. Market Snapshot
  • 6.2. Global T-Cell Lymphoma Market by Lymphoma Type, Performance - Potential Analysis
  • 6.3. Global T-Cell Lymphoma Market Estimates & Forecasts by Lymphoma Type 2019-2029 (USD Million)
  • 6.4. T-Cell Lymphoma Market, Sub Segment Analysis
    • 6.4.1. Peripheral T-cell Lymphoma
    • 6.4.2. T-cell Lymphoblastic Lymphoma

Chapter 7. Global T-Cell Lymphoma Market, by Therapy Type

  • 7.1. Market Snapshot
  • 7.2. Global T-Cell Lymphoma Market by Therapy Type, Performance - Potential Analysis
  • 7.3. Global T-Cell Lymphoma Market Estimates & Forecasts by Therapy Type 2019-2029 (USD Million)
  • 7.4. T-Cell Lymphoma Market, Sub Segment Analysis
    • 7.4.1. Radiotherapy
    • 7.4.2. Chemotherapy
    • 7.4.3. Immunotherapy
    • 7.4.4. Stem Cell Transplantation
    • 7.4.5. Other Types of Therapies

Chapter 8. Global T-Cell Lymphoma Market, Regional Analysis

  • 8.1. T-Cell Lymphoma Market, Regional Market Snapshot
  • 8.2. North America T-Cell Lymphoma Market
    • 8.2.1. U.S. T-Cell Lymphoma Market
      • 8.2.1.1. Lymphoma Type breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. Therapy Type breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada T-Cell Lymphoma Market
  • 8.3. Europe T-Cell Lymphoma Market Snapshot
    • 8.3.1. U.K. T-Cell Lymphoma Market
    • 8.3.2. Germany T-Cell Lymphoma Market
    • 8.3.3. France T-Cell Lymphoma Market
    • 8.3.4. Spain T-Cell Lymphoma Market
    • 8.3.5. Italy T-Cell Lymphoma Market
    • 8.3.6. Rest of Europe T-Cell Lymphoma Market
  • 8.4. Asia-Pacific T-Cell Lymphoma Market Snapshot
    • 8.4.1. China T-Cell Lymphoma Market
    • 8.4.2. India T-Cell Lymphoma Market
    • 8.4.3. Japan T-Cell Lymphoma Market
    • 8.4.4. Australia T-Cell Lymphoma Market
    • 8.4.5. South Korea T-Cell Lymphoma Market
    • 8.4.6. Rest of Asia Pacific T-Cell Lymphoma Market
  • 8.5. Latin America T-Cell Lymphoma Market Snapshot
    • 8.5.1. Brazil T-Cell Lymphoma Market
    • 8.5.2. Mexico T-Cell Lymphoma Market
    • 8.5.3. Rest of Latin America T-Cell Lymphoma Market
  • 8.6. Rest of The World T-Cell Lymphoma Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Genmab AS
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Johnson & Johnson (Janssen Pharmaceuticals Inc.)
    • 9.2.3. Mundipharma International, Limited
    • 9.2.4. Bristol-Myers Squibb Company
    • 9.2.5. Autolus Therapeutics PLC
    • 9.2.6. Acrotech Biopharma, Inc.
    • 9.2.7. Macopharma
    • 9.2.8. Merck & Co. Inc.
    • 9.2.9. F. Hoffmann-La Roche Ltd
    • 9.2.10. Novartis AG

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global T-Cell Lymphoma Market, report scope
  • TABLE 2. Global T-Cell Lymphoma Market estimates & forecasts by Region 2019-2029 (USD Million)
  • TABLE 3. Global T-Cell Lymphoma Market estimates & forecasts by Lymphoma Type 2019-2029 (USD Million)
  • TABLE 4. Global T-Cell Lymphoma Market estimates & forecasts by Therapy Type 2019-2029 (USD Million)
  • TABLE 5. Global T-Cell Lymphoma Market by segment, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 6. Global T-Cell Lymphoma Market by region, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 7. Global T-Cell Lymphoma Market by segment, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 8. Global T-Cell Lymphoma Market by region, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 9. Global T-Cell Lymphoma Market by segment, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 10. Global T-Cell Lymphoma Market by region, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 11. Global T-Cell Lymphoma Market by segment, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 12. Global T-Cell Lymphoma Market by region, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 13. Global T-Cell Lymphoma Market by segment, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 14. Global T-Cell Lymphoma Market by region, estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 15. U.S. T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 16. U.S. T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 17. U.S. T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 18. Canada T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 19. Canada T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 20. Canada T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 21. UK T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 22. UK T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 23. UK T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 24. Germany T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 25. Germany T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 26. Germany T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 27. France T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 28. France T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 29. France T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 30. Italy T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 31. Italy T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 32. Italy T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 33. Spain T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 34. Spain T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 35. Spain T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 36. RoE T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 37. RoE T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 38. RoE T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 39. China T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 40. China T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 41. China T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 42. India T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 43. India T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 44. India T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 45. Japan T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 46. Japan T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 47. Japan T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 48. South Korea T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 49. South Korea T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 50. South Korea T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 51. Australia T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 52. Australia T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 53. Australia T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 54. RoAPAC T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 55. RoAPAC T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 56. RoAPAC T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 57. Brazil T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 58. Brazil T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 59. Brazil T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 60. Mexico T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 61. Mexico T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 62. Mexico T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 63. RoLA T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 64. RoLA T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 65. RoLA T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 66. Row T-Cell Lymphoma Market estimates & forecasts, 2019-2029 (USD Million)
  • TABLE 67. Row T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 68. Row T-Cell Lymphoma Market estimates & forecasts by segment 2019-2029 (USD Million)
  • TABLE 69. List of secondary sources, used in the study of global T-Cell Lymphoma Market
  • TABLE 70. List of primary sources, used in the study of global T-Cell Lymphoma Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global T-Cell Lymphoma Market, research methodology
  • FIG 2. Global T-Cell Lymphoma Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global T-Cell Lymphoma Market, key trends 2021
  • FIG 5. Global T-Cell Lymphoma Market, growth prospects 2022-2029
  • FIG 6. Global T-Cell Lymphoma Market, porters 5 force model
  • FIG 7. Global T-Cell Lymphoma Market, pest analysis
  • FIG 8. Global T-Cell Lymphoma Market, value chain analysis
  • FIG 9. Global T-Cell Lymphoma Market by segment, 2019 & 2029 (USD Million)
  • FIG 10. Global T-Cell Lymphoma Market by segment, 2019 & 2029 (USD Million)
  • FIG 11. Global T-Cell Lymphoma Market by segment, 2019 & 2029 (USD Million)
  • FIG 12. Global T-Cell Lymphoma Market by segment, 2019 & 2029 (USD Million)
  • FIG 13. Global T-Cell Lymphoma Market by segment, 2019 & 2029 (USD Million)
  • FIG 14. Global T-Cell Lymphoma Market, regional snapshot 2019 & 2029
  • FIG 15. North America T-Cell Lymphoma Market 2019 & 2029 (USD Million)
  • FIG 16. Europe T-Cell Lymphoma Market 2019 & 2029 (USD Million)
  • FIG 17. Asia pacific T-Cell Lymphoma Market 2019 & 2029 (USD Million)
  • FIG 18. Latin America T-Cell Lymphoma Market 2019 & 2029 (USD Million)
  • FIG 19. Global T-Cell Lymphoma Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable